| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000009594 |
| Receipt No. | R000011212 |
| Official scientific title of the study | Randmized Controlled Trial for validity and safety to effect of high hemoglobin(Hb) level on kidney function post kidney transplant recipients. |
| Date of disclosure of the study information | 2012/12/21 |
| Last modified on | 2017/07/19 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | Randmized Controlled Trial for validity and safety to effect of high hemoglobin(Hb) level on kidney function post kidney transplant recipients. | |
| Title of the study (Brief title) | Clinical study in anemia post kidney transplant recipients | |
| Region |
|
|
| Condition | ||
| Condition | Chronic kidney disease after kidney transplantation | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To study the optimal range of anemia after kideny transplantation |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Difference between Hb normal group and Hb subnormal group in rate of decline in kidney function for 5 years |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Hb normal group
Target Hb level 13g/dl with erythropoietin stimulating agents(ESA) |
|
| Interventions/Control_2 | Hb subnormal group
Target Hb level 11g/dl with or without erythropoietin stimulating agents(ESA) |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.More than 1 year after kidney transplantation
2.Stable kidney function for at least 3 months 3.eGFR of 15-50 ml/min/1.73m2 4.Hb level of 9.0-11.5 g/dl with or without ESA 5.Patients who give written informed consent |
|||
| Key exclusion criteria | 1.Urine protein more than 1g/day
2.Deterionation of kidney function within the preceding 3 months 3.History of acute rejection within 3 months 4.Uncontrolled hypertension(systolic blood pressure>140,diastolic blood pressure>100) 5.Active or uncontrolled infection 6.Prior diagnosis of malignancy 7.Iron deficiency anemia 8.Hemorrhage diathesis 9.Hb<10g/dl with ESA 10.Pregnancy or lactation 11.History of myocardial infarctioin or angina pectoris 12.History of cerebral infarction with any symptom 13.Hypersensitivity reactions to ESA |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Yoshihiko Watarai |
| Organization | Nagoya Daini Red Cross Hospital |
| Division name | Transplant Surgery |
| Address | 2-9 Myoken-cho Syowa-ku Nagoya-shi |
| TEL | 052-832-1121 |
| watarai@nagoya2.jrc.or.jp | |
| Public contact | |
| Name of contact person | Makoto Tsujita |
| Organization | Nagoya Daini Red Cross Hospital |
| Division name | Transplant Surgery |
| Address | 2-9 Myoken-cho Syowa-ku Nagoya-shi |
| TEL | 052-832-1121 |
| Homepage URL | |
| tsujita4850@nagoya2.jrc.or.jp | |
| Sponsor | |
| Institute | Nagoya Daini Red Cross Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Nagoya Daini Red Cross Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Masuko Memorial Hospital |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000011212 |